The CHMP adopted a new pharmaceutical form associated with a new route of administration, tablets for oral use, in four new strengths (1.5 mg, 4 mg, 9 mg and 25 mg)
When they are ready for a more effective long-term solution, tirzepatide becomes the next step
Semaglutide is contraindicated in patients with: Personal or family history of medullary thyroid carcinoma (MTC) Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) Common Adverse Effects According to clinical trial data, gastrointestinal effects are most frequently reported: nausea, vomiting, diarrhea, constipation, and abdominal discomfort
It is not known whether these effects would occur in people
This approach encourages patients and providers to prioritize clinical efficacy over cost concerns during titration
Discard the pen if exposed to temperatures above 86F